Prolight Diagnostics AB (NGM:PRLD) NonCurrent Deferred Revenue: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:PRLD Prolight Diagnostics AB NGM:PRLD
31 GF Score
Price kr17.90
! 1 Warning Sign
View Full Analysis

What is Prolight Diagnostics AB NonCurrent Deferred Revenue?

Prolight Diagnostics AB NGM:PRLD +2.29% 31 NonCurrent Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Prolight Diagnostics AB's non-current deferred revenue for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Prolight Diagnostics AB NonCurrent Deferred Revenue Related Terms

Prolight Diagnostics AB NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Prolight Diagnostics AB's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prolight Diagnostics AB NonCurrent Deferred Revenue Chart

Prolight Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prolight Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:PRLD
31GF Score
Prolight Diagnostics AB NGM:PRLD
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of kr0.00 Mil mean?
Prolight Diagnostics AB (NGM:PRLD) has a NonCurrent Deferred Revenue of kr0.00 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Prolight Diagnostics AB and its competitors.
Is Prolight Diagnostics AB's NonCurrent Deferred Revenue too high?
Prolight Diagnostics AB's current NonCurrent Deferred Revenue is kr0.00 Mil. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's NonCurrent Deferred Revenue compare to ISRG and BDX?
Prolight Diagnostics AB's NonCurrent Deferred Revenue of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Prolight Diagnostics AB and its competitors. Prolight Diagnostics AB's current NonCurrent Deferred Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current NonCurrent Deferred Revenue of kr0.00 Mil. The current NonCurrent Deferred Revenue is kr0.00 Mil. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current NonCurrent Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prolight Diagnostics AB Business Description

Address Gasverksgatan 3A, Lund, SWE, 222 29
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score

Get the complete analysis for NGM:PRLD

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.90
Price